OSA is estimated to affect 2-3% of all children, with an increased prevalence reported in obese children. The first line of treatment for OSA in children remains adenotonsillectomy, however recent emerging evidence reveals that this treatment has limited efficacy in certain populations, including obese children. Accordingly, there becomes a need for additional therapeutic strategies, and in this context the role of OMT will be discussed.
1) List the 3 Ps of pediatric OSA: prevalence, its presentation and pathophysiology
2) Review the supporting evidence for current treatments and links between OSA and obesity
3) Include OMT in the treatment protocols of children with obesity and OSA.